TNFRSF9 and B-cell chronic lymphocytic leukemia: CTL019 as chimeric antigen receptor included a CD137 (4–1BB) signaling domain; infusion of such engineering T-cell was previously reported as promising in the treatment of chronic lymphocytic leukemia (CLL) [55].